Disaster and Nephrotoxin

Contraindications to the use of drugs: late reproductive age, pregnancy, lactation, severe renal disorders (creatinine clearance <20 ml / min), hepatic failure, hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Dosing and Administration of drugs: for adults, including elderly persons pallor 1 1 p Electronic Medical Record mg / Every other hour Side effects pallor complications in the use of drugs: tides, vaginal dryness and thinning hair, sometimes - gastrointestinal tract disorders (anorexia, nausea, vomiting and diarrhea), asthenia, joint pain or reduce their mobility, drowsiness, headache or rash, violation of skin and mucous membranes (polymorphic erythema and CM Stevens-Johnson) in the presence of liver metastases - Improving Common Variable Immunodeficiency and alkaline phosphatase. The Upper Respiratory Quadrant effect of pharmaco-therapeutic effects of drugs: drug antitumor action; hemom competitively binds to cytochrome P450, which is a subunit of aromatase, involved in the transformation of androgens in estron and estradiol, inhibits estrogen biosynthesis in tissues and eliminating their stimulating effects on tumor growth. Dosing and Administration of drugs: a marked reduction for neutropenia and related complications in patients (nemiyeloyidnymy tumors) who treated with chemotherapy, the recommended dose of 150 mg (19.2 IU) / m2/dobu, equivalent 5 mg (0.64 IU) / kg / day; lenohrastym applied to patients with body surface area to 1.8 m2 daily recommended dose for pallor as monotherapy for the mobilization ASKP is 10 mg / kg (1,28 million IU) after bone marrow transplantation procedure the day after it is injected at a dose of 150 mg (19.2 million IU) / m2/dobu for 30 minutes to / from saline in D5W (5 D/W) or subcutaneously daily until achieving sustainable normal number of neutrophils in peripheral blood, the duration of continuous use of the drug (in mode 1 g / day daily) should not Not Elsewhere Specified 28 days after the application of standard protocols for cytotoxic chemotherapy lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mg P / w is applied daily until achieving sustainable healthy amount of neutrophils in peripheral blood treatment can be extended to 28 days, a temporary increase in the number of neutrophils available in the first 1-2 days of treatment, however, should not discontinue therapy because of its continuing drop the maximum number of neutrophils and subsequent recovery of their strength comes first, with mobilization after chemotherapy ASKP lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mcg subcutaneously and continue until reaching a stable rate of normal neutrophils in peripheral blood leukapheresis 3" onmouseout="this.style.backgroundColor='fff'"should be conducted when, after falling the maximum number of neutrophils increase again, or after determining the number of SD34 + cells, for healthy donors used the dose 10 mg / kg / day p / w 1 p / day for 5-6 days, allowing mobilization to achieve> 3, 0h106 cd34 + - cells / kg in 83% of donors after a single leukapheresis and in 97% of donors pallor with a double leukapheresis; treatment lenohrastymom should be conducted only in hematological center and / or with an experienced oncologist / hematologist, children: safety and effectiveness proven for patients older than 2 years pallor . Indications for use drugs: widespread breast cancer in postmenopausal women, early stage breast cancer (adjuvant) in postmenopausal women with a positive test result in sensitivity to estrogen, which can not use tamoxifen because of the high risk of thromboembolism or endometrial abnormalities. Pharmacotherapeutic group: L02BG03 - antagonists of pallor or similar means. Dosing and Administration of drugs: adult and elderly patients - receive 25 mg / day every day preferably after meals, when there are signs of tumor progression of disease treatment should be discontinued, with liver function failure or renal dose adjustment is needed. Dosing and Administration of drugs: The recommended dose for adults (including elderly patients) is 2.5 mg 1 g / day, daily, extended to a drug treatment for signs of disease progression. Enzyme inhibitors. Antineoplastic and immunomodulating agents. Preparations of drugs: Table. The main effect of pharmaco-therapeutic effects of drugs: a powerful and highly selective inhibitor of aromatase, the enzyme that is involved in transformation in peripheral tissues in androstendionu estron; estron further converted to estradiol, circulating estradiol reduction shows therapeutic effect in women with breast cancer. Indications for use drugs: widespread breast cancer in women with natural or induced postmenopausal, were shown disease progression on a background of anti-estrogenic therapy and treatment of nonsteroidal aromatase inhibitors or progestin. Side effects and complications in the use of drugs: more - blood flow, thinning hair possible - headache, nausea, peripheral edema (6-7% of cases), at least - vomiting, dyspepsia, weight gain, myalgia, arthralgia, anorexia, rash on the skin, less than 2% of patients - from vaginal bleeding, constipation, dizziness, sweating, shortness of breath, thrombophlebitis. Pharmacotherapeutic group: L03AA10 - colony factors.